



GP 1633
NOV 13 2000

Please type or plus sign (+) inside this box → [] +

PTO/SB/21 (08-00) 00/2000

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/485,601
		Filing Date	May 4, 2000
		First Named Inventor	S. Strittmatter
		Group Art Unit	1633
		Examiner Name	D. Nguyen
Total Number of Pages in This Submission	4	Attorney Docket Number	OCR-842.US

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Mary M. Krinsky 79 Trumbull Street, New Haven, CT 06511-3708
Signature	
Date	November 10, 2000

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: Nov. 10, 2000

Typed or printed name	Mary M. Krinsky
Signature	
Date	11/10/00

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

OCR-842-JKS

TECH CENTER 1600/2901

11/21/00
11/21/00

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

STEPHEN M. STRITTMATTER

Serial No.: 09/485,601

Filed: May 4, 2000

: Art Unit 1633

: Examiner: D. Nguyen

For: CENTRAL NERVOUS SYSTEM AXON REGENERATION

Reply to a Restriction Requirement Under PCT Rule 13.1 and 37 C.F.R. § 1.143

Commissioner of Patents
and Trademarks
Washington, DC 20231

Dear Sir:

Please consider the following remarks sent in response to a Restriction Requirement dated 16 October 2000:

REMARKS

Claims 1 to 20 are pending in this application. In the above-referenced restriction requirement, these were divided into three groups:

Group I, claims 1, 2, 6-13, and 17, drawn to a protein therapy method of employing a rho protein inhibitor;

Group II, claims 1 to 18, drawn to a gene therapy method of employing a DNA vector comprising a rho protein inhibitor encoded DNA; and

Group III, claims 19 and 20, drawn to a screening method comprising assaying for rho protein inhibitory activity of a test compound.

I hereby certify that this document is today being sent as first class mail under 37 C.F.R. § 1.8, postage paid, to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

November 10, 2000

Mary M. Krinsky
Mary M. Krinsky